CN113166261A - B7h3单域抗体及其治疗性组合物 - Google Patents
B7h3单域抗体及其治疗性组合物 Download PDFInfo
- Publication number
- CN113166261A CN113166261A CN201980082130.5A CN201980082130A CN113166261A CN 113166261 A CN113166261 A CN 113166261A CN 201980082130 A CN201980082130 A CN 201980082130A CN 113166261 A CN113166261 A CN 113166261A
- Authority
- CN
- China
- Prior art keywords
- seq
- nos
- cdr2
- cdr1
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862744640P | 2018-10-11 | 2018-10-11 | |
| US62/744,640 | 2018-10-11 | ||
| US201962832274P | 2019-04-10 | 2019-04-10 | |
| US62/832,274 | 2019-04-10 | ||
| US201962877812P | 2019-07-23 | 2019-07-23 | |
| US62/877,812 | 2019-07-23 | ||
| PCT/US2019/055427 WO2020076970A1 (en) | 2018-10-11 | 2019-10-09 | B7h3 single domain antibodies and therapeutic compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113166261A true CN113166261A (zh) | 2021-07-23 |
Family
ID=68318988
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980082130.5A Pending CN113166261A (zh) | 2018-10-11 | 2019-10-09 | B7h3单域抗体及其治疗性组合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230124851A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3864044A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2022512684A (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166261A (cg-RX-API-DMAC7.html) |
| CA (1) | CA3115082A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202028246A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020076970A1 (cg-RX-API-DMAC7.html) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113980143A (zh) * | 2021-11-02 | 2022-01-28 | 深圳先进技术研究院 | 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用 |
| WO2023061417A1 (en) * | 2021-10-12 | 2023-04-20 | Concept To Medicine Biotech Co., Ltd. | Cd3-targeting t-cell engagers with improved therapeutic index |
| WO2024061297A1 (en) * | 2022-09-22 | 2024-03-28 | Shanghai Henlius Biotech , Inc. | Anti-b7h3 antibodies, multispecific antibodies and methods of use |
| CN118702816A (zh) * | 2024-06-03 | 2024-09-27 | 广州泽朗生物医药科技有限公司 | 一种nk细胞及其在抗肿瘤治疗中的应用 |
| WO2025112030A1 (zh) * | 2023-12-01 | 2025-06-05 | 苏州智核生物医药科技有限公司 | B7h3结合多肽及其用途 |
| WO2025157244A1 (zh) * | 2024-01-25 | 2025-07-31 | 山东先声生物制药有限公司 | 抗b7h3抗体及其应用 |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY200973A (en) | 2017-04-11 | 2024-01-26 | Inhibrx Inc | Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same |
| TW202010757A (zh) | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
| WO2020023553A1 (en) | 2018-07-24 | 2020-01-30 | Inhibrx, Inc. | Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same |
| JP7611820B2 (ja) | 2018-10-11 | 2025-01-10 | インヒブルクス バイオサイエンシズ インコーポレイテッド | Dll3シングルドメイン抗体およびその治療用組成物 |
| US12590169B2 (en) | 2018-10-11 | 2026-03-31 | Inhibrx Biosciences, Inc. | 5T4 single domain antibodies and therapeutic compositions thereof |
| EP4097129A1 (en) * | 2020-01-29 | 2022-12-07 | Inhibrx, Inc. | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| WO2022002038A1 (zh) * | 2020-06-30 | 2022-01-06 | 和铂医药(上海)有限责任公司 | 免疫细胞衔接器多特异性结合蛋白及其制备和应用 |
| EP4545569A3 (en) * | 2020-06-30 | 2025-10-08 | Harbour Biomed (Shanghai) Co., Ltd | Binding protein having h2l2 and hcab structures |
| CN111662384B (zh) | 2020-06-30 | 2021-04-09 | 广州百暨基因科技有限公司 | 抗b7h3抗体及其应用 |
| TWI818276B (zh) * | 2020-06-30 | 2023-10-11 | 大陸商和鉑醫藥(上海)有限責任公司 | Fab-HCAb結構的結合蛋白 |
| US11919958B2 (en) | 2020-08-19 | 2024-03-05 | Xencor, Inc. | Anti-CD28 compositions |
| CN117321087A (zh) | 2021-03-26 | 2023-12-29 | 先天制药公司 | 包含与细胞因子融合用于nk细胞衔接的nkp46结合位点、癌抗原结合位点的多特异性蛋白质 |
| CA3215429A1 (en) * | 2021-04-06 | 2022-10-13 | Unicet Biotech Co. Llc | Methods to improve stability of virus transduction of .gamma..delta. t cells and applications thereof |
| WO2022258678A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a |
| CN117616050A (zh) | 2021-06-09 | 2024-02-27 | 先天制药公司 | 与nkp46、细胞因子受体、肿瘤抗原和cd16a结合的多特异性蛋白质 |
| WO2022258691A1 (en) | 2021-06-09 | 2022-12-15 | Innate Pharma | Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a |
| AU2022301099A1 (en) * | 2021-07-01 | 2024-02-15 | Ningbo T-Maximum Biopharmaceuticals Co., Ltd. | Antigen-binding polypeptide targeting b7h3 and application thereof |
| JPWO2023100944A1 (cg-RX-API-DMAC7.html) * | 2021-12-01 | 2023-06-08 | ||
| IL314993A (en) | 2022-02-23 | 2024-10-01 | Xencor Inc | Anti-cd28 x anti-psma antibodies |
| JP2025526677A (ja) * | 2022-08-08 | 2025-08-15 | ティクヴァ アロセル プライベート リミテッド | B7-h3抗原結合性分子 |
| JP2025531402A (ja) * | 2022-09-22 | 2025-09-19 | シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド | 抗b7h3抗体及び使用方法 |
| TW202428608A (zh) * | 2022-12-29 | 2024-07-16 | 英屬開曼群島商百濟神州有限公司 | 抗b7h3抗體以及其使用方法 |
| TW202430568A (zh) * | 2022-12-29 | 2024-08-01 | 英屬開曼群島商百濟神州有限公司 | 抗b7h3抗體以及其使用方法 |
| WO2024208818A1 (en) | 2023-04-04 | 2024-10-10 | Innate Pharma | Modular chimeric antigen receptor |
| TW202528354A (zh) * | 2024-01-03 | 2025-07-16 | 中國商北京泰德製藥股份有限公司 | B7-h3結合蛋白及其用途 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2026086929A1 (zh) * | 2024-10-24 | 2026-04-30 | 北京科诺信诚科技有限公司 | 靶向人b7h3的纳米抗体及其应用 |
| WO2026128367A1 (en) * | 2024-12-09 | 2026-06-18 | Y-Mabs Therapeutics, Inc. | Tumor binding molecules and the use thereof for the diagnosis and treatment of cancer |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| DE3414831A1 (de) | 1984-04-19 | 1985-10-31 | Hoechst Ag, 6230 Frankfurt | Herstellung von polypeptiden mit human-gammainterferon-aktivitaet |
| DE3536939A1 (de) | 1985-10-17 | 1987-04-23 | Hoechst Ag | Biologisch aktive derivate des human-(gamma)-interferons, ihre herstellung und arzneimittel, die solche derivate enthalten |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| DE4036856C1 (cg-RX-API-DMAC7.html) | 1990-11-19 | 1992-05-27 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung Ev, 8000 Muenchen, De | |
| US5525491A (en) | 1991-02-27 | 1996-06-11 | Creative Biomolecules, Inc. | Serine-rich peptide linkers |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5637481A (en) | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| US7381803B1 (en) | 1992-03-27 | 2008-06-03 | Pdl Biopharma, Inc. | Humanized antibodies against CD3 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5770191A (en) | 1995-05-24 | 1998-06-23 | University Of Florida | Active C-terminal peptides of interferon--gamma and their use |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| GB9815909D0 (en) | 1998-07-21 | 1998-09-16 | Btg Int Ltd | Antibody preparation |
| EP1002861A1 (en) | 1998-10-26 | 2000-05-24 | Unilever Plc | Antigen-binding proteins comprising a linker which confers restricted conformational flexibility |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| FR2822845B1 (fr) | 2001-03-30 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides comportant des polymorphismes de type snp fonctionnels dans la sequence nucleotidique du gene ifn-alpha-21 ainsi que de nouveaux polypeptides codes par ces polynucleotides et leurs utilisations therapeutiques |
| FR2823763A1 (fr) | 2001-04-18 | 2002-10-25 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'interferon alpha 6 |
| FR2823764B1 (fr) | 2001-04-24 | 2003-12-12 | Genodyssee | Nouveaux polynucleotides et polypeptides du gene ifn alpha-17 |
| FR2824333B1 (fr) | 2001-05-03 | 2003-08-08 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 5 |
| FR2825102B1 (fr) | 2001-05-23 | 2003-08-29 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'interferon alpha 14 |
| FR2825716B1 (fr) | 2001-06-11 | 2004-09-24 | Genodyssee | Nouveaux polynucleotides et polypeptides de l'ifn alpha 7 |
| US7647184B2 (en) | 2001-08-27 | 2010-01-12 | Hanall Pharmaceuticals, Co. Ltd | High throughput directed evolution by rational mutagenesis |
| EP1391213A1 (en) | 2002-08-21 | 2004-02-25 | Boehringer Ingelheim International GmbH | Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents |
| CA2498284A1 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational directed protein evolution using two-dimensional rational mutagenesis scanning |
| WO2004022593A2 (en) | 2002-09-09 | 2004-03-18 | Nautilus Biotech | Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| JP3803790B2 (ja) | 2003-02-17 | 2006-08-02 | 株式会社東北テクノアーチ | 新規なダイアボディ型二重特異性抗体 |
| US8076459B2 (en) | 2003-10-16 | 2011-12-13 | Micromet Ag | Multispecfic deimmunized CD3-binders |
| DK1678314T3 (da) | 2003-10-22 | 2012-12-03 | Keck Graduate Inst | Fremgangsmåde til syntetisering af heteromultimere polypeptider i gær ved anvendelse af en haploid parringsstrategi |
| PT1718677E (pt) | 2003-12-19 | 2012-07-18 | Genentech Inc | Fragmentos de anticorpo monovalentes úteis como agentes terapêuticos |
| CN1961003B (zh) | 2004-03-31 | 2013-03-27 | 健泰科生物技术公司 | 人源化抗TGF-β抗体 |
| WO2005100402A1 (en) | 2004-04-13 | 2005-10-27 | F.Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| SG188175A1 (en) | 2004-06-03 | 2013-03-28 | Novimmune Sa | Anti-cd3 antibodies and methods of use thereof |
| US20060024272A1 (en) | 2004-07-29 | 2006-02-02 | Large Scale Biology Corporation | C-terminally truncated interferon |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| US20100111856A1 (en) | 2004-09-23 | 2010-05-06 | Herman Gill | Zirconium-radiolabeled, cysteine engineered antibody conjugates |
| GB0510790D0 (en) | 2005-05-26 | 2005-06-29 | Syngenta Crop Protection Ag | Anti-CD16 binding molecules |
| AU2006291005A1 (en) | 2005-09-12 | 2007-03-22 | Novimmune S.A. | Anti-CD3 antibody formulations |
| WO2008119567A2 (en) | 2007-04-03 | 2008-10-09 | Micromet Ag | Cross-species-specific cd3-epsilon binding domain |
| EP2190861A4 (en) | 2007-08-22 | 2011-03-30 | Univ California | ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE |
| AU2008329518A1 (en) | 2007-11-27 | 2009-06-04 | Viventia Biotechnologies Inc. | Antibodies against a cancer-associated epitope of variant NFKBIB and uses thereof |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| AU2009299794B2 (en) | 2008-10-01 | 2015-08-13 | Amgen Research (Munich) Gmbh | Cross-species-specific single domain bispecific single chain antibody |
| EP3543256A1 (en) | 2009-01-12 | 2019-09-25 | Cytomx Therapeutics Inc. | Modified antibody compositions, methods of making and using thereof |
| US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
| TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
| PH12012501751A1 (en) | 2010-03-04 | 2012-11-12 | Macrogenics Inc | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| WO2011133886A2 (en) | 2010-04-23 | 2011-10-27 | Genentech, Inc. | Production of heteromultimeric proteins |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| EP2703486B1 (en) * | 2011-04-25 | 2018-03-07 | Daiichi Sankyo Company, Limited | Anti-b7-h3 antibody |
| WO2012162067A2 (en) * | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Cd3-binding molecules capable of binding to human and non-human cd3 |
| WO2013026837A1 (en) | 2011-08-23 | 2013-02-28 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| US20150239991A1 (en) | 2012-09-25 | 2015-08-27 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| CA2889951C (en) | 2012-11-02 | 2023-04-18 | Zymeworks Inc. | Crystal structures of heterodimeric fc domains |
| EA032681B1 (ru) | 2012-11-27 | 2019-07-31 | Аджоу Юниверсити Индастри-Академик Кооперейшн Фаундейшн | ГЕТЕРОДИМЕР Fc ИММУНОГЛОБУЛИНА, СОДЕРЖАЩИЙ ВАРИАНТ ДОМЕНА CH3 ДЛЯ ОБРАЗОВАНИЯ АНТИТЕЛА ИЛИ ГИБРИДНОГО БЕЛКА С ГЕТЕРОМЕРНЫМ Fc С ВЫСОКОЙ ЭФФЕКТИВНОСТЬЮ, СПОСОБ ДЛЯ ЕГО ПОЛУЧЕНИЯ И ИСПОЛЬЗОВАНИЯ |
| US9803021B2 (en) | 2012-12-07 | 2017-10-31 | The Regents Of The University Of California | CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities |
| US9703815B2 (en) | 2012-12-17 | 2017-07-11 | Salesforce.Com, Inc. | Third party files in an on-demand database service |
| KR20150095684A (ko) | 2012-12-18 | 2015-08-21 | 노파르티스 아게 | 히알루로난에 결합하는 펩티드 태그를 이용하는 조성물 및 방법 |
| KR102391731B1 (ko) | 2013-01-14 | 2022-04-27 | 젠코어 인코포레이티드 | 신규한 이형이량체 단백질 |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US9701759B2 (en) | 2013-01-14 | 2017-07-11 | Xencor, Inc. | Heterodimeric proteins |
| US9562099B2 (en) | 2013-03-14 | 2017-02-07 | Genentech, Inc. | Anti-B7-H4 antibodies and immunoconjugates |
| EP3587448B1 (en) | 2013-03-15 | 2021-05-19 | Xencor, Inc. | Heterodimeric proteins |
| US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
| US10093745B2 (en) | 2013-05-29 | 2018-10-09 | The Regents Of The University Of California | Anti-CSPG4 fusions with interferon for the treatment of malignancy |
| KR102813816B1 (ko) | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| JP6693872B2 (ja) | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| KR20250051130A (ko) | 2013-09-25 | 2025-04-16 | 싸이톰스 테라퓨틱스, 인크. | 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법 |
| HUE050159T2 (hu) | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| WO2015095412A1 (en) | 2013-12-19 | 2015-06-25 | Zhong Wang | Bispecific antibody with two single-domain antigen-binding fragments |
| EP3628328B1 (en) | 2014-01-31 | 2022-09-14 | Cytomx Therapeutics Inc. | Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof |
| EP3149040A1 (en) * | 2014-05-29 | 2017-04-05 | Spring Bioscience Corporation | Anti-b7-h3 antibodies and diagnostic uses thereof |
| CA2955947A1 (en) | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| WO2016019300A1 (en) * | 2014-07-31 | 2016-02-04 | Novartis Ag | Subset-optimized chimeric antigen receptor-containing t-cells |
| KR102485788B1 (ko) * | 2014-08-27 | 2023-01-09 | 메모리얼 슬로안 케터링 캔서 센터 | 항체, 조성물 및 용도 |
| JP6696982B2 (ja) * | 2014-11-26 | 2020-05-20 | ゼンコー・インコーポレイテッドXencor、 Inc. | Cd3および腫瘍抗原に結合するヘテロ二量体抗体 |
| ES2935274T3 (es) | 2014-12-05 | 2023-03-03 | Merck Patent Gmbh | Anticuerpo con intercambio de dominios |
| IL300408B2 (en) | 2015-01-20 | 2025-11-01 | Cytomx Therapeutics Inc | Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof |
| EP3247407A4 (en) | 2015-01-21 | 2018-08-22 | Inhibrx LP | Non-immunogenic single domain antibodies |
| WO2016192613A1 (zh) * | 2015-06-01 | 2016-12-08 | 中山大学 | 具有融合至常规Fab片段的单域抗原结合片段的二价抗体 |
| EP3310811B1 (en) | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| EP3325512B1 (en) | 2015-07-23 | 2023-09-06 | Inhibrx, Inc. | Multivalent and multispecific gitr-binding fusion proteins |
| JP2018523686A (ja) | 2015-08-17 | 2018-08-23 | マクロジェニクス,インコーポレーテッド | B7‐h3及びcd3に結合できる二重特異性1価ダイアボディ並びにその使用 |
| MY195059A (en) | 2015-09-23 | 2023-01-05 | Regeneron Pharma | Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof |
| IL300122A (en) * | 2015-11-18 | 2023-03-01 | Merck Sharp ַ& Dohme Llc | Substances that bind to PD1 and/or LAG3 |
| IL304871A (en) * | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| JP7328761B2 (ja) | 2016-01-11 | 2023-08-17 | インヒブルクス インコーポレイテッド | 多価多重特異性ox40結合融合タンパク質 |
| GB201602156D0 (en) | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| KR102530742B1 (ko) | 2016-05-20 | 2023-05-09 | 하푼 테라퓨틱스, 인크. | 단일 도메인 혈청 알부민 결합 단백질 |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| WO2018027025A1 (en) | 2016-08-03 | 2018-02-08 | Oncomed Pharmaceuticals, Inc. | Cd40-binding agents and uses thereof |
| WO2018068201A1 (en) | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
| CN109843927B (zh) * | 2017-03-06 | 2022-06-21 | 江苏恒瑞医药股份有限公司 | 抗b7-h3抗体、其抗原结合片段及其医药用途 |
| EP3732199A1 (en) | 2017-12-27 | 2020-11-04 | TeneoBio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
| TW202010757A (zh) * | 2018-04-11 | 2020-03-16 | 美商英伊布里克斯公司 | 具有經受限cd3結合的多重特異性多肽構築體以及相關方法及用途 |
-
2019
- 2019-10-09 CN CN201980082130.5A patent/CN113166261A/zh active Pending
- 2019-10-09 TW TW108136773A patent/TW202028246A/zh unknown
- 2019-10-09 CA CA3115082A patent/CA3115082A1/en active Pending
- 2019-10-09 WO PCT/US2019/055427 patent/WO2020076970A1/en not_active Ceased
- 2019-10-09 EP EP19791442.7A patent/EP3864044A1/en active Pending
- 2019-10-09 US US17/283,902 patent/US20230124851A1/en not_active Abandoned
- 2019-10-09 JP JP2021520197A patent/JP2022512684A/ja not_active Ceased
-
2024
- 2024-08-30 JP JP2024148159A patent/JP2024167342A/ja active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023061417A1 (en) * | 2021-10-12 | 2023-04-20 | Concept To Medicine Biotech Co., Ltd. | Cd3-targeting t-cell engagers with improved therapeutic index |
| CN113980143A (zh) * | 2021-11-02 | 2022-01-28 | 深圳先进技术研究院 | 靶向cd276的嵌合抗原受体、嵌合抗原受体t细胞及制备方法和制药应用 |
| WO2024061297A1 (en) * | 2022-09-22 | 2024-03-28 | Shanghai Henlius Biotech , Inc. | Anti-b7h3 antibodies, multispecific antibodies and methods of use |
| WO2025112030A1 (zh) * | 2023-12-01 | 2025-06-05 | 苏州智核生物医药科技有限公司 | B7h3结合多肽及其用途 |
| WO2025157244A1 (zh) * | 2024-01-25 | 2025-07-31 | 山东先声生物制药有限公司 | 抗b7h3抗体及其应用 |
| CN118702816A (zh) * | 2024-06-03 | 2024-09-27 | 广州泽朗生物医药科技有限公司 | 一种nk细胞及其在抗肿瘤治疗中的应用 |
| CN118702816B (zh) * | 2024-06-03 | 2025-03-28 | 内蒙古正德缘生物科技有限责任公司 | 一种nk细胞及其在抗肿瘤治疗中的应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3864044A1 (en) | 2021-08-18 |
| WO2020076970A1 (en) | 2020-04-16 |
| CA3115082A1 (en) | 2020-04-16 |
| JP2024167342A (ja) | 2024-12-03 |
| JP2022512684A (ja) | 2022-02-07 |
| US20230124851A1 (en) | 2023-04-20 |
| TW202028246A (zh) | 2020-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7611820B2 (ja) | Dll3シングルドメイン抗体およびその治療用組成物 | |
| JP7789002B2 (ja) | Cd28シングルドメイン抗体ならびにその多価および多重特異性の構築物 | |
| TWI856030B (zh) | Pd-1單一域抗體及其之治療組合物 | |
| JP2024167342A (ja) | B7h3シングルドメイン抗体およびその治療用組成物 | |
| TWI863932B (zh) | 5t4單域抗體及其治療性組合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240925 Address after: California, USA Applicant after: Yinxibi Bioscience Co.,Ltd. Country or region after: U.S.A. Address before: California, USA Applicant before: INHIBRX L.P. Country or region before: U.S.A. |